MCA-derived MSCs therapy(Cynata Therapeutics)

N/A

Report date: 2024/09/19 17:35:07

Base Information

Drug NameMCA-derived MSCs therapy(Cynata Therapeutics)

Drug Alias NameCYP-002CYP 002

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Mesenchymoangioblast-derived

Mechanisms of ActionStem cell replacements

TargetsUpdating

Therapy Area/IndicationsIschemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCynata Therapeutics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesCynata Therapeutics Ltd

Inactive CompaniesN/A

Active IndicationsIschemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A